---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-024313"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T09:55:19.968725+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Femasys gets Australian & New Zealand approvals for FemaSeed and FemVue

## Summary
- Regulatory approvals granted for FemaSeed first-line intratubal insemination treatment and FemVue diagnostic.
- CEO Kathy Lee-Sepsick cites expanded global access and meaningful commercial opportunities.
- Approvals validate clinical value of platform and reinforce commitment to accessible infertility solutions.
- Company expects to grow revenue and broaden global footprint with these regulatory milestones.

## SEC filing metadata
- accession: 0001140361-25-024313
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125024313/0001140361-25-024313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125024313/ef20051434_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-024313
- JSON: https://secwatch.observer/filing/0001140361-25-024313.json
- Plain text: https://secwatch.observer/filing/0001140361-25-024313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.